May 2019 Volume 15, Issue 5

Volume 15, Issue 5 | May 2019

May 2019

In this Issue

Editor's Focus

Drug Discovery News Placeholder Image

Editor's focus: Vaccines increasingly under perilous scrutiny

Vaccines hardly deserve the suspicion they're being faced with of late, but developers need to keep their standards high and meet it nonetheless

Business & Government Policy

Drug Discovery News Placeholder Image

A hefty price tag for NLRP3

Novartis snaps up subsidiary IFM Tre and trio of NLRP3 antagonist molecules
Drug Discovery News Placeholder Image

Wings Therapeutics launches

ProQR spins out all dystrophic epidermolysis bullosa activities
Drug Discovery News Placeholder Image

On the cutting edge

A roundup of instrumentation, software and other tools and technology news
Drug Discovery News Placeholder Image

Eisai buys out Purdue rights

Move officially ends collaboration on sleep-wake regulation agent
Drug Discovery News Placeholder Image

Patent Docs: A Solution in Search of a Problem

Kevin Noonan discusses the Biologic Patent Transparency Act and how he thinks the U.S. Congress might be picking the wrong target (patents) as a way to decrease drug prices and increase transparency

Discovery

Drug Discovery News Placeholder Image

Interest in inosine

ALS cells lose critical enzyme that protects neuronal cells
Drug Discovery News Placeholder Image

Machine learning vs. NASH

Gilead Sciences and insitro launch collaboration for AI-enabled drug discovery against NASH
Drug Discovery News Placeholder Image

Keep a good thing going

Expanded collaboration in Huntington’s disease research to explore stem cell and genetic therapeutics
Drug Discovery News Placeholder Image

Managing the microbiome

A roundup of a few recent news stories related to microbiome discoveries
Drug Discovery News Placeholder Image

A fifth collaboration for AI-driven firm

Ono and twoXAR announce neurological drug discovery deal

Research & Development

Drug Discovery News Placeholder Image

Disruptive double agent

Existing drug may successfully treat aggressive tumor
Drug Discovery News Placeholder Image

Through the ages

Two unique research paths emerge, looking at the fundamentals of aging and ancient origins of disease
Drug Discovery News Placeholder Image

Splice-Break finds key DNA deletions

A new approach to studying deletions in the mitochondria could inform disease study
Drug Discovery News Placeholder Image

A booster for immuno-oncology drugs

Australia’s Noxopharm unveils preclinical results on idronoxil

Feature

Drug Discovery News Placeholder Image

At the forefront of cancer research

We look at FLIP, STING and other potentially groundbreaking areas of oncology therapeutics R&D
Drug Discovery News Placeholder Image

ISSCR Show Preview: Sunny days for stem cells

ISSCR makes its way to sunny L.A. for its 17th annual meeting

Clinical Trials

Drug Discovery News Placeholder Image

Bile acid modulation

Drug aids in reducing rare pediatric liver disease
Drug Discovery News Placeholder Image

Plenty of momentum for inarigivir

Spring Bank reports positive response from ACHIEVE trial, kicks off CATALYST trials
Drug Discovery News Placeholder Image

Guselkumab goes into development for FAP

MorphoSys announces that licensee Janssen has expanded clinical development of drug into familial adenomatous polyposis
Drug Discovery News Placeholder Image

Improving the experimental landscape

CRA and TLS’ VISITOR take different paths toward road to clinical trials, success of new drugs

Q&A

Drug Discovery News Placeholder Image

Q&A: Concern as NAFLD and NASH rates rise

DDNews speaks with Mount Sinai researcher about the past, present and future of these liver conditions

Contract Services

Drug Discovery News Placeholder Image

Modeling proteins better

Sygnature Discovery announces collaboration with software firm SilcsBio
Drug Discovery News Placeholder Image

A platform partnership

CrownBio and HUB ink license agreement to offer their PDX and organoid platforms together
Drug Discovery News Placeholder Image

Vetter’s Skokie facility expansion nears completion

Facility growth is necessary to help meet customer demands and new product requirements

Diagnostics

Drug Discovery News Placeholder Image

Real-world data vs. MS

Clinico-genomic collaboration propels multiple sclerosis research
Drug Discovery News Placeholder Image

Predicting obesity?

Researchers may be able to use genetic profiles to predict obesity risk at birth
Drug Discovery News Placeholder Image

Getting more eyes on glaucoma

Mannin Research, Biointerfaces Institute to pursue GDF15 biomarker diagnostic for eye disease
Drug Discovery News Placeholder Image

Homing in on PTSD

IU researchers discover potential test for post-traumatic stress disorder

Preclinical

Drug Discovery News Placeholder Image

Triggering clean-up lessens inflammation

Inhibiting choline kinase leads to mitophagy, which could stave off inflammasome activation
Drug Discovery News Placeholder Image

Notable results for NYX-458

Data in Parkinson’s disease model demonstrate reversal of cognitive deficits with NYX-458
Drug Discovery News Placeholder Image

Advancing apace with ADAPTIR

Aptevo advances bispecific candidates, sees encouraging preclinical data
Drug Discovery News Placeholder Image

A gene therapy for wet AMD

Adverum presents first preclinical data on dosing contralateral eye with ADVM-022

Commentary

Drug Discovery News Placeholder Image

Out of Order: Of mice and…well…other mice

Trying to present the news without too much fanfare (and with maximum accuracy) means resisting temptation, but it's effort well-spent
Drug Discovery News Placeholder Image

Guest Commentary: Moving beyond regulatory analytical requirements for better biotherapeutics

There are several analytical methods that must be developed for biotherapeutics; among the most important of these are host cell proteins
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue